Biomarkers in Cancer Detection and Monitoring of Therapeutics
Volume 1: Discovery and Technologies
- 1st Edition - November 16, 2023
- Latest edition
- Editors: Ranbir Chander Sobti, Awtar Krishan, Aastha Sobti
- Language: English
Biomarkers in Cancer Detection and Monitoring of Therapeutics, Volume One, Discovery and Technologies discusses how molecular biomarkers are used to determine predis… Read more
World Book Day celebration
Where learning shapes lives
Up to 25% off trusted resources that support research, study, and discovery.
Description
Description
Biomarkers in Cancer Detection and Monitoring of Therapeutics, Volume One, Discovery and Technologies discusses how molecular biomarkers are used to determine predisposition, facilitate detection, improve treatment and offer prevention guidelines for different cancer types. This first volume in the series focuses on techniques and approaches recently developed to assist in the decision of which biomarker to use for specific conditions. Topics covered include circulating tumor cells and circulating tumor DNA, exomes, tumor microenvironment, gene editing, artificial intelligence and robotics. In addition, the book discusses the development and applications of organoids and precision medicine.This book will be a valuable resource for cancer researchers, oncologists, graduate students and members of the biomedical field who are interested in the potential of biomarkers in cancer research.
Key features
Key features
- Provides up-to-date information on current molecular biomarkers research for cancer
- Presents basic research aspects and novel technologies applied in the discovery of new biomarkers
- Discusses several technologies, including artificial intelligence, robotics, data mining, gene editing, omics and their applicability for specific cancer types
Readership
Readership
Researchers and graduate students on cancer research, oncologists, Clinical researchers
Table of contents
Table of contents
1. CANCER BURDEN: EPIDEMIOLOGY, RACIAL AND GEOGRAPHICAL DISPARITIES
Shaveta Menon and Ramila Bisht
2. MILESTONES IN CANCER RESEARCH
Siddharth Sharma
3. TECHNOLOGICAL EVOLUTION IN CANCER DIAGNOSISAND THERAPEUTICS
Sudeep Bose I
4. HOW DOES TIME SPEAK ABOUT CANCER, ITS DIAGNOSIS, TREATMENTS AND CHALLENGES?
Asit Ranjan Ghosh
5. ROLE OF ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS AND THERAPEUTICS
B. Medhi
6. ADDRESSING THE DIAGNOSIS AND THERAPEUTICS OF MALIGNANT TUMOUR CELLS
Anjoy Mahji
7. SOMATIC MUTATION: PHARMACOGENOMICS IN ONCOLOGY CARE
Shamsher Singh
8. INSIGHTS INTO GENETIC PREDISPOSITION OF SOMATIC CANCERS
B. Medhi
9. THE USE OF TUMOR MARKERS IN PROGNOSIS OF CANCER AND STRATEGIES TO PREVENT CANCER PREDISPOSITION AND PROGRESS
Osama Ahmed, Mohamed Abd-Elbaset, Noha Ahmed and Eman Abd Elhaliem
10. CYTOGENETICS TO MULTI-OMICS IN BIOLOGY OF CANCER
Sikander S. Gill
11. ROLE OF NON-CODING RNA AS BIOMARKERS FOR CANCER
Bikash Medhi and B. Medhi
12. VIRAL miRNA's: DIAGNOSTIC AND PROGNOSTIC BIOMARKERS FOR CANCER AND INFECTIOUS DISEASE
Sunil Babu Gosipatala, Dr. Abhishek Pandeya, Raj Kumar Khalko, Ranbir C. Sobti Sr., Sneha Kumari, Prashansa Khanna and Utkarsha Vishwakarma
13. PHARMACOGENOMICS AND ONCOLOGY: A THERAPEUTIC APPROACH FOR CANCER TREATMENT
Shamsher Singh and Anil Kumar
14. ENVIRONMENTAL FACTORS INFLUENCING EPIGENETIC CHANGES INITIATING NEOPLASTIC CHANGES
B. Medhi
15. OBESITY: EMERGING RISK FACTOR FOR CANCER BEYOND METABOLIC SYNDROME
Ranbir C. Sobti Sr.
16. HOMOLOGOUS REPAIR DEFICIENCY AND PARP INHIBITORS IN CANCER MANAGEMENT
Shivani Arora Mittal
17. MOLECULAR PROSPECTS OF TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR NUCLEASES (TALENS) IN CANCER
Mani Chopra
18. IMMUNO PEPTIDOMIC APPROACHES FORMANAGEMENT OFCANCER
B. Medhi
19. REGULATION OF TUMOR MICROENVIRONMENT BY NUTRIENT TRAFFICKING
B. Medhi
20. PRECISION MEDICINE : DOSE FOR ANTI CANCER THERAPY
Dr Shiva Tushir
Shaveta Menon and Ramila Bisht
2. MILESTONES IN CANCER RESEARCH
Siddharth Sharma
3. TECHNOLOGICAL EVOLUTION IN CANCER DIAGNOSISAND THERAPEUTICS
Sudeep Bose I
4. HOW DOES TIME SPEAK ABOUT CANCER, ITS DIAGNOSIS, TREATMENTS AND CHALLENGES?
Asit Ranjan Ghosh
5. ROLE OF ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS AND THERAPEUTICS
B. Medhi
6. ADDRESSING THE DIAGNOSIS AND THERAPEUTICS OF MALIGNANT TUMOUR CELLS
Anjoy Mahji
7. SOMATIC MUTATION: PHARMACOGENOMICS IN ONCOLOGY CARE
Shamsher Singh
8. INSIGHTS INTO GENETIC PREDISPOSITION OF SOMATIC CANCERS
B. Medhi
9. THE USE OF TUMOR MARKERS IN PROGNOSIS OF CANCER AND STRATEGIES TO PREVENT CANCER PREDISPOSITION AND PROGRESS
Osama Ahmed, Mohamed Abd-Elbaset, Noha Ahmed and Eman Abd Elhaliem
10. CYTOGENETICS TO MULTI-OMICS IN BIOLOGY OF CANCER
Sikander S. Gill
11. ROLE OF NON-CODING RNA AS BIOMARKERS FOR CANCER
Bikash Medhi and B. Medhi
12. VIRAL miRNA's: DIAGNOSTIC AND PROGNOSTIC BIOMARKERS FOR CANCER AND INFECTIOUS DISEASE
Sunil Babu Gosipatala, Dr. Abhishek Pandeya, Raj Kumar Khalko, Ranbir C. Sobti Sr., Sneha Kumari, Prashansa Khanna and Utkarsha Vishwakarma
13. PHARMACOGENOMICS AND ONCOLOGY: A THERAPEUTIC APPROACH FOR CANCER TREATMENT
Shamsher Singh and Anil Kumar
14. ENVIRONMENTAL FACTORS INFLUENCING EPIGENETIC CHANGES INITIATING NEOPLASTIC CHANGES
B. Medhi
15. OBESITY: EMERGING RISK FACTOR FOR CANCER BEYOND METABOLIC SYNDROME
Ranbir C. Sobti Sr.
16. HOMOLOGOUS REPAIR DEFICIENCY AND PARP INHIBITORS IN CANCER MANAGEMENT
Shivani Arora Mittal
17. MOLECULAR PROSPECTS OF TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR NUCLEASES (TALENS) IN CANCER
Mani Chopra
18. IMMUNO PEPTIDOMIC APPROACHES FORMANAGEMENT OFCANCER
B. Medhi
19. REGULATION OF TUMOR MICROENVIRONMENT BY NUTRIENT TRAFFICKING
B. Medhi
20. PRECISION MEDICINE : DOSE FOR ANTI CANCER THERAPY
Dr Shiva Tushir
Product details
Product details
- Edition: 1
- Latest edition
- Published: November 16, 2023
- Language: English
About the editors
About the editors
RS
Ranbir Chander Sobti
Dr. Ranbir Chander (RC) Sobti is Emeritus Professor at Punjab University, Chandigarh, and Honorary Scientist at the Indian National Science Academy. He started his career as a cytogeneticist and progressed to molecular biology and disease processes of cancer, COPD, AIDS, metabolic syndrome, and kidney diseases. He is a Fellow of the Third World Academy of Sciences, National Academy of Sciences India, Indian National Science Academy, National Academy of Medical Sciences, National Academy of Agricultural Sciences, Canadian Academy of Cardiovascular Diseases Royal Society of biology and international Association of Cancer Research. Dr. Sobti has participated in several book projects, including Elsevier’s Advances in Animal Experimentation and Modeling; Biomarkers in Cancer Detection and Monitoring of Therapeutics; Molecular Medicine and Biomedical Research in the Era of Precision Medicine; One Planet, One Health, One Future; Probiotics; and Public and Environmental Health.
Affiliations and expertise
Professor (Emeritus), Department of Biotechnology, Panjab University, Chandigarh, IndiaAK
Awtar Krishan
Dr. Awtar Krishan PhD is a world-renowned scientist. He obtained his PhD from Panjab University (1962) and the Univ. of Western Ontario, Canada (1963) in Cytogenetics and Anatomy. From 1965 to 1977, he was at the Sidney Farber Cancer Institute, Harvard Medical School as Head of the Tissue Ultrastructure and Experimental Pathology Labs. He has developed flow cytometric techniques for rapid analysis of DNA content by hypotonic propidium iodide, monitoring of drug retention and resistance, and more recently for monitoring hormone receptor expression in archival tumors. He is currently Director, Analytical Cytometry Laboratory, at University of Miami.
Affiliations and expertise
Professor, Sylvester Comprehensive Cancer Center, University of Miami Health System, USAAS
Aastha Sobti
Aastha Sobti is a Doctoral student at the Department of Immunotechnology at Lund University, Sweden. Her research areas interests include translational medicine, clinical dentistry, cancer immunology, biomarkers, diagnostics and medical oncology. Aastha Sobti has written two books with Elsevier: "Biomarkers in Cancer Detection and Monitoring of Therapeutics" (2023) and Molecular Medicine and Biomedical Research in the Era of Precision Medicine (2025).
Affiliations and expertise
Doctoral student, Department of Immunotechnology, Lund University, Lund, SwedenView book on ScienceDirect
View book on ScienceDirect
Read Biomarkers in Cancer Detection and Monitoring of Therapeutics on ScienceDirect